Medium urgency

Tempus AI receives FDA clearance for pulmonary hypertension tool - mobihealthnews.com

Detected September 2, 2026 · in Healthcare AI Regulation (FDA / ONC)

Tempus AI has received FDA clearance for its pulmonary hypertension tool, marking a significant advancement in health AI applications.

Aforeworn detected this change in the Healthcare AI Regulation (FDA / ONC) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Health systems, medical device companies, health tech startups, and digital health compliance teams. should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Healthcare AI Regulation (FDA / ONC) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FDA clearance granted to Tempus AI for a new pulmonary hypertension tool, allowing its use in clinical settings.

Who it affects

Health systems, medical device companies, health tech startups, and digital health compliance teams.

What you must do

Evaluate the implications of this FDA clearance on your own AI tools and compliance requirements.

Deadline

N/A

Source: https://news.google.com/rss/articles/CBMinAFBVV95cUxNeTZtb0RWSkVlTmdHYVFZalpHM1UtNVlVYVVGeFpsSVZTQUpwaWRFT0ZHZGI4NlFaekVTM08zM2I4bHJFVGZIVGQ3WVRRcDUyMU94VjZ6akxtTURKak5yUl9FaHUxN01lQS1ydzlDRmpvMTgtMnEtTkN6WGhweFhuWC1mbXlGOThzOHRiS1JMUEZpSlJ6clotZlZGRVE?oc=5

Never miss a change like this again

Aforeworn watches Healthcare AI Regulation (FDA / ONC) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Healthcare AI Regulation (FDA / ONC)